|  |  |
| --- | --- |
| **MEETING SUBJECT:** | **PINTAD 2017 April Teleconference** |
| **DATE / TIME:** | **28 April 17 / 11:00 AM EST** |
| **PREPARED BY:** | **Annette Schmid** |
| **LOCATION:** | **Teleconference** |

**MEETING SUMMARY**

DISCUSSION POINTS:

|  |  |
| --- | --- |
| **1** | **Welcome** |
| **2** | **Dr Thomas Balzer,** VP, Head Global Medical & Clinical Affairs Radiology at Bayer Healthcare will provide an **overview about the process and background to EMA’s Pharmacovigilance and Risk Assessment Committee (PRAC) on linear gadolinium compounds.** Dr Balzer provided a brief overview of the data available from animal and human trials on long term effects of gadolinium contrast. He noted the differences in observed stability of linear versus macrocyclic gadolinium contrast. Ending with an overview of the EMA process in the context of PRAC recommendations.While slides for this presentation are not available, specific questions should be directed to Dr Thomas Balzer.  |
| **3** | **Next meeting** **Friday, 28JUL17 11:00 am ET** |